112 related articles for article (PubMed ID: 18365884)
1. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation.
Myschik J; McBurney WT; Hennessy T; Phipps-Green A; Rades T; Hook S
J Drug Target; 2008 Apr; 16(3):224-32. PubMed ID: 18365884
[TBL] [Abstract][Full Text] [Related]
2. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
3. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol.
Myschik J; McBurney WT; Rades T; Hook S
Int J Pharm; 2008 Nov; 363(1-2):91-8. PubMed ID: 18692555
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part I: Physicochemical characterisation.
Myschik J; Eberhardt F; Rades T; Hook S
J Drug Target; 2008 Apr; 16(3):213-23. PubMed ID: 18365883
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A.
Myschik J; McBurney WT; Hennessy T; Rades T; Hook S
Pharmazie; 2008 Sep; 63(9):686-92. PubMed ID: 18819523
[TBL] [Abstract][Full Text] [Related]
7. Impact of implant composition of twin-screw extruded lipid implants on the release behavior.
Even MP; Bobbala S; Kooi KL; Hook S; Winter G; Engert J
Int J Pharm; 2015 Sep; 493(1-2):102-10. PubMed ID: 26188320
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable implants for the delivery of veterinary vaccines: design, manufacture and antibody responses in sheep.
Walduck AK; Opdebeeck JP; Benson HE; Prankerd R
J Control Release; 1998 Feb; 51(2-3):269-80. PubMed ID: 9685925
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.
White K; Rades T; Kearns P; Toth I; Hook S
Pharm Res; 2006 Jul; 23(7):1473-81. PubMed ID: 16779706
[TBL] [Abstract][Full Text] [Related]
10. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses.
Rizwan SB; McBurney WT; Young K; Hanley T; Boyd BJ; Rades T; Hook S
J Control Release; 2013 Jan; 165(1):16-21. PubMed ID: 23142776
[TBL] [Abstract][Full Text] [Related]
11. Leaf saponins of Quillaja brasiliensis enhance long-term specific immune responses and promote dose-sparing effect in BVDV experimental vaccines.
Cibulski S; Rivera-Patron M; Suárez N; Pirez M; Rossi S; Yendo AC; de Costa F; Gosmann G; Fett-Neto A; Roehe PM; Silveira F
Vaccine; 2018 Jan; 36(1):55-65. PubMed ID: 29174676
[TBL] [Abstract][Full Text] [Related]
12. Simple nanoliposomes encapsulating
Bo R; Sun Y; Zhou S; Ou N; Gu P; Liu Z; Hu Y; Liu J; Wang D
Int J Nanomedicine; 2017; 12():6289-6301. PubMed ID: 28894367
[TBL] [Abstract][Full Text] [Related]
13. Salidroside liposome formulation enhances the activity of dendritic cells and immune responses.
Zhao X; Lu Y; Tao Y; Huang Y; Wang D; Hu Y; Liu J; Wu Y; Yu Y; Liu C
Int Immunopharmacol; 2013 Dec; 17(4):1134-40. PubMed ID: 24188805
[TBL] [Abstract][Full Text] [Related]
14. Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy.
Even MP; Bobbala S; Gibson B; Hook S; Winter G; Engert J
Eur J Pharm Biopharm; 2017 May; 114():79-87. PubMed ID: 28104440
[TBL] [Abstract][Full Text] [Related]
15. Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice.
Sun HX; Pan HJ
Vaccine; 2006 Mar; 24(11):1914-20. PubMed ID: 16300865
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells.
Lipford GB; Wagner H; Heeg K
Vaccine; 1994 Jan; 12(1):73-80. PubMed ID: 8303944
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antigen-specific CD4
Weilhammer D; Dunkle AD; Blanchette CD; Fischer NO; Corzett M; Lehmann D; Boone T; Hoeprich P; Driks A; Rasley A
Vaccine; 2017 Mar; 35(11):1475-1481. PubMed ID: 28214044
[TBL] [Abstract][Full Text] [Related]
18. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
Johnston D; Bystryn JC
Vaccine; 2006 Mar; 24(11):1958-65. PubMed ID: 16310898
[TBL] [Abstract][Full Text] [Related]
19. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
20. Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma.
Highton AJ; Kojarunchitt T; Girardin A; Hook S; Kemp RA
Immunol Cell Biol; 2015 Aug; 93(7):634-40. PubMed ID: 25708538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
